Michele Tana, MD

TitleAssistant Professor
InstitutionUniversity of California San Francisco
Address1001 Potrero Ave
San Francisco CA 94110
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard CollegeA.B.2000Classics
    Harvard UniversityM.D.2005Medical Schoool
    Duke UniversityM.H.S.2016Clinical Research
    Stanford UniversityInternal Medicine2008School of Medicine
    California Pacific Medical CenterGastroenterology2011Department of Medicine
    National Institutes of HealthHepatology2013NIDDK

    Collapse Overview 
    Collapse Overview
    Michele Tana grew up in Northern Virginia. She studied the Classics at Harvard College, then went to Harvard Medical School. She did her Internal Medicine training at Stanford University Hospital and Clinics and her gastroenterology fellowship at California Pacific Medical Center. She spent two years at the National Institutes of Health as a Clinical Fellow in the National Institute of Diabetes and Digestive and Kidney Diseases, Liver Diseases Branch, then joined the UCSF faculty at San Francisco General Hospital in 2013. She is a clinician-educator with an interest in clinical and translational research. She collaborates with researchers across many disciplines to study autoimmune liver diseases, alcoholic liver disease, and hepatocellular carcinoma.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lee B, Holt EW, Wong RJ, Sewell JL, Somsouk M, Khalili M, Maher JJ, Tana M. Race/ethnicity is an independent risk factor for autoimmune hepatitis among the San Francisco underserved. Autoimmunity. 2018 Jun 11; 1-7. PMID: 29890851.
      View in: PubMed
    2. Wen JW, Kohn MA, Wong R, Somsouk M, Khalili M, Maher J, Tana M. Hospitalizations for Autoimmune Hepatitis Disproportionately Affect Black and Latino Americans. Am J Gastroenterol. 2018 Feb; 113(2):243-253. PMID: 29380822.
      View in: PubMed
    3. Baghdanian AH, Baghdanian AA, Puppala S, Tana M, Ohliger MA. Imaging Manifestations of Peptic Ulcer Disease on Computed Tomography. Semin Ultrasound CT MR. 2018 Apr; 39(2):183-192. PMID: 29571554.
      View in: PubMed
    4. Tana M, Alao H, Morris N, Bernstein S, Hattenbach J, Brychta R, Sarkar S, Zhao X, Walter M, Buckley A, Chen K, Rotman Y.Fatigued Patients with Chronic Liver Disease Have Subtle Aberrations of Sleep, Melatonin and Cortisol Circadian Rhythms. Fatigue: Biomedicine, Health & Behavior. 2017; 6(1):5-19.
    5. Tana M, Muir AJ. Diagnosing Liver Fibrosis and Cirrhosis: Serum, Imaging, or Tissue? Clin Gastroenterol Hepatol. 2018 Jan; 16(1):16-18. PMID: 28694131.
      View in: PubMed
    6. van Wijk XMR, Magee CA, Wu AHB, Tana M, Lynch KL. A comparison of methods for evaluation of a case of suspected macro-aspartate aminotransferase. Clin Chim Acta. 2016 Dec 01; 463:1-3. PMID: 27732874.
      View in: PubMed
    7. Ha J, Yan M, Aguilar M, Bhuket T, Tana M, Liu B, Gish RG, Wong RJ. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. Cancer. 2016 08 15; 122(16):2512-23. PMID: 27195481.
      View in: PubMed
    8. Ha J, Yan M, Aguilar M, Tana M, Liu B, Frenette CT, Bhuket T, Wong RJ. Race/Ethnicity-specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis and its Impact on Receipt of Curative Therapies. J Clin Gastroenterol. 2016 May-Jun; 50(5):423-30. PMID: 26583267.
      View in: PubMed
    9. Tana M, Shums Z, Milo J, Norman GL, Leung PS, Gershwin ME, Noureddin M, Kleiner DE, Zhao X, Heller T, Hoofnagle JH. The Significance of Autoantibody Changes Over Time in Primary Biliary Cirrhosis. Am J Clin Pathol. 2015 Oct; 144(4):601-6. PMID: 26386081.
      View in: PubMed
    10. Tana M, Zhao X, Bradshaw A, Moon MS, Page S, Turner T, Rivera E, Kleiner DE, Heller T. Factors associated with the platelet count in patients with chronic hepatitis C. Thromb Res. 2015 May; 135(5):823-8. PMID: 25728497.
      View in: PubMed
    11. Tana M, Heller T. Autoantibodies in hepatitis C: red flag or bystander effect? J Pediatr Gastroenterol Nutr. 2013 Mar; 56(3):243. PMID: 23443062.
      View in: PubMed
    12. Tana M, Hoofnagle JH. Scar undone: long-term therapy of hepatitis B. Lancet. 2013 Feb 09; 381(9865):433-4. PMID: 23234726.
      View in: PubMed